Sanofi betting on Lantus heir; EU OKs Boehringer cancer drug; Leo Burnett gets Pfizer biz;

Sanofi sign

@FiercePharma: Another Fresenius plant gets warning letter. This time in PR, on repeat labeling probs. Article from FiercePharmaManufacturing | Follow @FiercePharma

> Sanofi's ($SNY) Pierre Chancel, senior VP, global diabetes, says the drugmaker is expecting its improved version of Lantus to offset the biosimilar threat to the blockbuster. Story

> The FDA has strengthened the hepatitis B warning on GlaxoSmithKline's ($GSK) Arzerra and Roche's ($RHHBY) and Biogen Idec's ($BIIB) Rituxan. Report

> Boehringer Ingelheim has received EU approval for its targeted lung cancer drug Giotrif for specific patient populations. Story

> Bayer has been criticized by the U.K.'s Prescription Medicines Code of Practice Authority for paying for nightcaps for delegates at a conference in Amsterdam. Story

> A case against Japan's Takeda over the cancer risks of taking its diabetes drug Actos has gone to the jury in Baltimore, MD. Story

> Europe is at risk of a reintroduction of polio because of frequent travel between there and Israel, where the disease has been found in multiple samples of sewage. Story

Medical Device News

@FierceMedDev: EU committee backs tougher, U.S.-style device approval system. Article | Follow @FierceMedDev

@MarkHFierce: FierceDiagnostics has another great crop of stories. Check it out | Follow @MarkHFierce

@MichaelGFierce: Study: Artificial pancreas with inhaled insulin improves glucose control. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Olympus looks to the future with launch of sinus surgery tool. More

> Medtronic takes Insulet's settlement in insulin pump patent spat. Story

> Klobuchar, Hatch: Not so fast on device tax repeal. Article

> Roche, Pacific Biosciences seal $75M clinical Dx partnership. Item

Biotech News

@FierceBiotech: Eli Lilly will eventually have to come to grips with the fact that its R&D strategy and execution has been woeful. Story | Follow @FierceBiotech

@JohnCFierce: IPO 2013 revival update: 37 biotechs out, $2.8B raised from IPOs. More on the way. Feature | Follow @JohnCFierce

@DamianFierce: Merged at last on KKR's dime, PRA and RPS say they're the world's fourth-largest CRO. Article from FierceCRO | Follow @DamianFierce

@EmilyMFierce: $25M NIH project will set up genomic variants database for clinical use. More from FierceBiotech Research | Follow @EmilyMFierce

> Rise of personalized drugs means fewer 'dinosaur' trials. Item

> Merck KGaA amps up next-gen antibody pact with Ablynx. More

> Ipsen joins crowd in Cambridge with R&D move. Article

Pharma Manufacturing News

@EricPFierce: Kashmir-born Ph.D. picked by FDA to head office in India where problems mount. Story | Follow @EricPFierce

> Pfizer dumping plant, 140 workers in Australia. Item

> Sanofi building its largest African plant in Algeria. Report

> Purdue building $59M plant in North Carolina. More

> J&J says more Doxil shortages imminent, tied to Ben Venue problems. Story

> FDA warning points to infrastructure issue in India. Article

Vaccines News

> Merck KGaA lung cancer vaccine to re-enter Phase III. Item

> GSK, Merck and Pfizer join JP Morgan vaccine investment fund. Report

> European prices reapply old pressures to vaccine makers. Story

> Pandemic leads researchers to universal flu vaccine 'blueprint.' More

> U.K. gov makes U-turn on link between GSK vaccine and narcolepsy. Article

And Finally... Leo Burnett Vietnam has won Pfizer's ($PFE) advertising business in a competition with 5 other competitors, including Lowe and Ogilvy. Story